MicroRNA Monitoring in Human Alveolar Macrophages from Patients with Smoking-Related Lung Diseases: A Preliminary Study.

COPD alveolar macrophages lung cancer microRNAs smoking-related diseases

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
09 May 2024
Historique:
received: 08 04 2024
revised: 18 04 2024
accepted: 01 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is commonly considered to be a potent driver of non-small cell lung cancer (NSCLC) development and related mortality. A growing body of evidence supports a role of the immune system, mainly played by alveolar macrophages (AMs), in key axes regulating the development of COPD or NSCLC phenotypes in response to harmful agents. MicroRNAs (miRNAs) are small non-coding RNAs that influence most biological processes and interfere with several regulatory pathways. The purpose of this study was to assess miRNA expression patterns in patients with COPD, NSCLC, and ever- or never-smoker controls to explore their involvement in smoking-related diseases. Bronchoalveolar lavage (BAL) specimens were collected from a prospective cohort of 43 sex-matched subjects to determine the expressions of hsa-miR-223-5p, 16-5p, 20a-5p, -17-5p, 34a-5p and 106a-5p by RT-PCR. In addition, a bioinformatic analysis of miRNA target genes linked to cancer was performed. Distinct and common miRNA expression levels were identified in each pathological group, suggesting their possible role as an index of NSCLC or COPD microenvironment. Moreover, we identified miRNA targets linked to carcinogenesis using in silico analysis. In conclusion, this study identified miRNA signatures in AMs, allowing us to understand the molecular mechanisms underlying smoking-related conditions and potentially providing new insights for diagnosis or pharmacological treatment.

Identifiants

pubmed: 38791013
pii: biomedicines12051050
doi: 10.3390/biomedicines12051050
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Davida Mirra (D)

Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", 81100 Caserta, Italy.

Renata Esposito (R)

Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", 81100 Caserta, Italy.

Giuseppe Spaziano (G)

Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", 81100 Caserta, Italy.

Liberata Sportiello (L)

Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, 80138 Naples, Italy.
Department of Experimental Medicine-Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Francesca Panico (F)

Department of Health Sciences, University of "Magna Graecia", 88100 Catanzaro, Italy.

Antonio Squillante (A)

Department of Medicine, University of Salerno, 84100 Salerno, Italy.

Maddalena Falciani (M)

Pulmonary and Critical Care Medicine, Ospedale Scarlato, 84018 Scafati, Italy.

Ida Cerqua (I)

Department of Pharmacy, University Federico II of Naples, Via D. Montesano 49, 80131 Naples, Italy.

Luca Gallelli (L)

Department of Health Sciences, University of "Magna Graecia", 88100 Catanzaro, Italy.

Erika Cione (E)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.

Bruno D'Agostino (B)

Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", 81100 Caserta, Italy.

Classifications MeSH